Ticks aren’t all bad! Check out the Business of Biotech podcast to hear how Akari engineered #nomacopan, a recombinant protein derived from ticks, and scaled …
[Read more...] about Akari on the Business of Biotech podcast
Akari Therapeutics to Participate in the Ophthalmology Day at BTIG
NEW YORK and LONDON, November 22, 2022(GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics to Participate in the Ophthalmology Day at BTIG
Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA
NEW YORK and LONDON, November 10, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
Akari Therapeutics to Participate in the Jefferies London Healthcare Conference
NEW YORK and LONDON, November 9, 2022 (GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics to Participate in the Jefferies London Healthcare Conference
Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer
• Dr. Neylan has more than 20 years of experience in the development of biologic treatments from pre-clinical to post-marketing trials …
